EGFR and neoplasm: Although high-level amplifications of the proto-oncogene MET are uncommon in previously untreated NSCLC (~3% [74]), MET amplifications have been detected in 5–20% of tumor samples from patients with acquired resistance following first-line EGFR TKI therapy, and have been implicated in tumor cell proliferation and survival [35, 59, 75–82].